Skip to content
★ Sign in to follow
Gufic Biosciences Limited logo

Gufic Biosciences Limited Stock: price and insider trades · India

IN·Mcap ₹39BHealth Care

No insider purchase over the last 90 days. The latest, by Mrs. Vipula J. Choksi, was filed 08 Jun 2021.

Gufic Biosciences Limited: what insiders have been doing

Gufic Biosciences Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEBI (PIT + SAST). The past year has been quiet: not a single insider filing for Gufic Biosciences Limited. The previous disclosure was published on 3 June 2022.

For comparison within the same sector, see the insider buying recorded at Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€215,153
3 ops. · all time
Sell Volume
€1M
4 ops. · all time

Since the insiders bought

  • Filed 08 Jun 2021 · 1980 days ago · €80k
    +21.8%
    Entry ₹183.60 · Close at T+365 ₹223.70
  • Filed 08 Jun 2021 · 1980 days ago · €80k
    +21.8%
    Entry ₹183.60 · Close at T+365 ₹223.70
  • Filed 08 Jun 2021 · 1980 days ago · €54k
    +21.8%
    Entry ₹183.60 · Close at T+365 ₹223.70

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 16,301 of 26,913 companies
45.0
score / 100
Value
31
Quality
59
FCF yld0.3%
Earn yld1.6%
EV/EBITDA29.2x
ROE10%
Gross mgn46%
Net mgn7.9%
Debt/EBITDA2.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹389.00
Analyst consensus
·
Income statement
Revenue₹9.4B
Gross profit₹5.2B55% margin
EBITDA₹1.5B16% margin
Net income₹642.1M6.8% margin
Valuation
PER (trailing)60.9x
P/Book5.9x
Beta-0.04
Balance sheet & cash
Market cap₹39B
Total debt₹4B
Free Cash Flow₹137.9M
Debt / Equity61%
Profitability & ownership
ROE10.1%
ROA6.0%
% insiders77.5%
% institutions3.3%
Last declaration on 3 June 2022
Declarations7 total
  • ▼
    Executives
    4M INR2SEBI
    18,000 shares@ ₹220.42533.9% of flowEquity SharesSEBI:493695d46546f678999d809a50b941f94ffbb779
  • ▼
    Executives
    98M INR10SEBI
    450,000 shares@ ₹217.646596.1% of flowEquity SharesSEBI:51ad21351354d733ab586d3740b62710c4644ab7
  • ▲
    Executives
    7M INR25SEBI
    7,148,570 shares@ ₹1.00100.0% of flowEquity SharesSEBI:d58e6e029c9f547b5f7200d1b4400cf24002bdf2
    Canonical exit: 5 Sept 2021 (T+90)
  • ▲
    Executives
    7M INR25SEBI
    7,148,570 shares@ ₹1.00100.0% of flowEquity SharesSEBI:ba718e123ca1ed7b745f51e878396c06e735a158
    Canonical exit: 5 Sept 2021 (T+90)
  • ▲
    Related company / holdingExecutives
    5M INR25SEBI
    4,817,366 shares@ ₹1.00100.0% of flowEquity SharesSEBI:e24b652c77ee490507ab93106f57c1f4de656bda
    Canonical exit: 5 Sept 2021 (T+90)
  • 0Equity SharesSEBI:c6c85b7863ec453db354b785b9352eed00d4ad6b
  • ▼
    Executives
    0SEBI
    0Equity SharesSEBI:4e582a9b8c45cd482639310bb2e118b3ea2ba64d

7 of 7 declarations

About Gufic Biosciences Limited

Gufic Biosciences Limited is a company operating in the healthcare and pharmaceutical sector. It focuses on the research, development, and manufacturing of pharmaceutical products.